Mobile

A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Interf...

Update Il y a 4 ans
Reference: EUCTR2006-005972-42

A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Interferon beta-1a) with ibuprofen pro re nata (PRN) or as prophylaxis

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To assess subject satisfaction by the MS Treatment Concern Questionnaire (MSTCQ) specifically measuring Flu Like Symptoms (FLS) during the first 4 weeks after subjects transitioned to RNF in 2 treatment groups: one treatment group receives ibuprofen prophylactically and the other ibuprofen PRN.

Inclusion criteria

  • Relapsing Multiple Sclerosis

Links